1. Synthesis and biological evaluation of a novel pyroglutamyl-modified TRH analogue
- Author
-
Grazia Luisi, A. Giorgi, Luigi Brunetti, Francesco Pinnen, Alessandra Spirito, Lucia Recinella, Silvestro Duprè, Ivana Cacciatore, P. Sozio, A. Di Stefano, Giustino Orlando, and Barbara Michelotto
- Subjects
Male ,Stereochemistry ,Dopamine ,Pyroglutamyl-Peptidase I ,Pharmaceutical Science ,Peptide ,Residue (chemistry) ,chemistry.chemical_compound ,Pituitary Gland, Anterior ,Drug Discovery ,Peptide synthesis ,Animals ,Moiety ,Pyroglutamyl-peptidase I ,Rats, Wistar ,Nuclear Magnetic Resonance, Biomolecular ,Thyrotropin-Releasing Hormone ,Cells, Cultured ,chemistry.chemical_classification ,Dipeptide ,Dose-Response Relationship, Drug ,Biological activity ,Prolactin ,Pyrrolidonecarboxylic Acid ,Rats ,chemistry ,Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ,Cattle ,Pyroglutamic acid - Abstract
The TRH analogue 3, incorporating the (S)-isothiazolidine-1,1-dioxide-3-carboxylic acid (1) moiety in place of the native L-pyroglutamic acid (pGlu) residue, has been synthesized and fully characterized by 1H and 13C NMR. The effects of replacing pGlu with its sulphonamido counterpart on biological activity have been investigated. This peptide, which is significantly stabilized towards hydrolysis by pyroglutamyl peptidase type I (PP I, EC 3.4.19.3), has shown to maintain in vitro prolactin-releasing activity.
- Published
- 2002
- Full Text
- View/download PDF